Hokkaido

我们是谁

  • 1 月 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • 7 月 26, 2022
    一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究
  • 5 月 23, 2022
    索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤(KRAS)p.G12C 突变患者(代码 300)
  • 4 月 5, 2022
    Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    Repotrectinib(TPX-0005)对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)